ISU SPECIALTY CHEMICAL CO., LTD. Q3 revenue KRW 92.1 billion, operating loss KRW 4.5 billion
AI summary · Not investment advice
Isu Specialty Chemical sold KRW 92.1 billion in Q3 and lost KRW 4.5 billion on its main business; sales fell 11.5% from a year earlier and 14.8% from the prior quarter.
Operating profit · 3 months
KRW -4.5 billion
Key facts
- Revenue (3 months)
- KRW 92.1 billion
- Net income (3 months)
- KRW -3.9 billion
- Period
- Q3 (cumulative 2026.01.01 ~ 2026.09.30)
- Revenue (prior-year 3 months)
- KRW 104.0 billion
- Revenue (year to date)
- KRW 308.7 billion
- Operating profit (prior-year 3 months)
- KRW -1.5 billion
- Operating profit (year to date)
- KRW 6.7 billion
- Net income (prior-year 3 months)
- KRW -1.8 billion
- Net income (year to date)
- KRW 1.6 billion
Commentary
AI commentary · Not investment advice
What happened
Isu Specialty Chemical reported its consolidated results for the third quarter. Sales for the latest 3 months were KRW 92.05 billion. That is 11.5% lower than the same 3 months a year earlier (KRW 103.99 billion). It is also 14.8% lower than the previous quarter.
In the company's terms
Operating profit (profit from the core business) for the 3 months was a loss of KRW 4.49 billion. The previous quarter was profitable, so this is a swing to a loss. The same period a year earlier showed a loss of KRW 1.46 billion. Net income (final profit after taxes and other items) for the 3 months was a loss of KRW 3.89 billion. That is also a swing to a loss from the previous quarter. A year earlier it was a loss of KRW 1.82 billion.
What changes for shareholders
For the year to date, sales were KRW 308.65 billion. Operating profit was KRW 6.73 billion. Net income was KRW 1.63 billion.
Comments
No comments yet
Comments from shareholders will appear here.
Ad
Verify your holdings and catch the next disclosure
Verify the stocks you hold and get new disclosures as app alerts.

App design sample
Get the next disclosure as an app alert
Get app alerts for new disclosures and stake changes on your watchlist
I